摘要
目的探讨普罗布考与阿托伐他汀两种药物协同应用于脑梗死急性发作时的疗效以及两种药物对氧化型低密度脂蛋白(ox-LDL)和颈动脉内膜中膜厚度(IMT)的影响。方法将120例急性脑梗死患者纳入研究样本,采用随机且自愿的原则将其分为对照组与观察组,各60例。其中对照组予以基础对症处理加以阿托伐他汀药物治疗,观察组在其基础上联用普罗布考与阿托伐他汀两药。治疗时间均为6个月,以ox-LDL、IMT和神经功能缺损评分(NIHSS)等相关指标评价治疗后两组的整体疗效。结果经治疗后,观察组血清ox-LDL、hs-PCR、MMP-9较对照组均显著降低(P<0.05);观察组IMT和斑块面积较对照组均显著减小(P<0.05);观察组NIHSS评分较对照组均显著降低(P<0.05)。结论在阿托伐他汀基础上加用普罗布考对于急性脑梗死的治疗具有更优的临床效果,对动脉粥样硬化斑块的抑制效果更好,建议临床推广。
Objective To investigate the efficacy of probucol and atorvastatin in the acute onset of cerebral infarction and the effects of two drugs on oxidized low density lipoprotein(ox-LDL)and carotid intima-media thickness(The impact of IMT).Methods A total of 120 patients with acute cerebral infarction admitted to our hospital from February 2016 to February 2019 were enrolled in the study.They were randomly divided into the control group and the observation group,60 cases each.The patients in the control group were treated with basal symptomatic treatment with atorvastatin.The patients in the observation group were combined with probucol and atorvastatin.The treatment time was 6 months.The overall efficacy of the two groups after treatment was evaluated by ox-LDL,IMT and neurological deficit score(NIHSS).Results After treatment,the serum levels of ox-LDL,hs-PCR and MMP-9 in the observation group were significantly lower than those in the control group(P<0.05).The IMT and plaque area of the observation group were significantly lower than those of the control group(P<0.05).The NIHSS score of the observation group was significantly lower than that of the control group(P<0.05).Conclusion The addition of probucol to atorvastatin has a better clinical effect on the treatment of acute cerebral infarction,and it has better inhibitory effect on atherosclerotic plaque.It is recommended to be clinically popularized.
作者
周鹏
姜玉红
付艳红
Zhou Peng;Jiang Yuhong;Fu Yanhong(Department of Brain,Chinese Medicine Hospital of Sui Xian,Shangqiu 476900,China)
出处
《哈尔滨医药》
2020年第5期413-415,共3页
Harbin Medical Journal